La traducción aún no está lista. Se muestra el artículo original.
Amgen AMGN reported third-quarter 2026 adjusted earnings of $6.45 per share, up 14% year over year, driven primarily by higher revenues, which offset the impact of higher costs. Earnings per share beat the Zacks Consensus Estimate of $5.74. Total revenues increased 8% year over year to $10.37 billion, surpassing the consensus estimate of $9.95 billion. Product sales grew 8% to $9.88 billion, driven by higher volumes. Seventeen products delivered double-digit sales growth during the quarter. AMGN's Bone and Heart Drugs Deliver Strong Growth Repatha sales surged 37% year over year to $1.09 billion, exceeding the Zacks Consensus Estimate of $1.04 billion. The increase was driven by volume growth.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.